Sequent Scientific Limited

NSEI:SEQUENT Stock Report

Market Cap: ₹30.7b

Sequent Scientific Balance Sheet Health

Financial Health criteria checks 4/6

Sequent Scientific has a total shareholder equity of ₹6.8B and total debt of ₹4.6B, which brings its debt-to-equity ratio to 67.5%. Its total assets and total liabilities are ₹15.0B and ₹8.2B respectively.

Key information

67.5%

Debt to equity ratio

₹4.61b

Debt

Interest coverage ration/a
Cash₹598.81m
Equity₹6.83b
Total liabilities₹8.18b
Total assets₹15.01b

Recent financial health updates

Recent updates

Revenues Not Telling The Story For Sequent Scientific Limited (NSE:SEQUENT)

Apr 05
Revenues Not Telling The Story For Sequent Scientific Limited (NSE:SEQUENT)

Sequent Scientific (NSE:SEQUENT) Has A Somewhat Strained Balance Sheet

Mar 10
Sequent Scientific (NSE:SEQUENT) Has A Somewhat Strained Balance Sheet

Is Sequent Scientific's (NSE:SEQUENT) 177% Share Price Increase Well Justified?

Jan 31
Is Sequent Scientific's (NSE:SEQUENT) 177% Share Price Increase Well Justified?

How Much Did Sequent Scientific's (NSE:SEQUENT) CEO Pocket Last Year?

Jan 17
How Much Did Sequent Scientific's (NSE:SEQUENT) CEO Pocket Last Year?

Sequent Scientific Limited's (NSE:SEQUENT) Stock Is Going Strong: Have Financials A Role To Play?

Jan 05
Sequent Scientific Limited's (NSE:SEQUENT) Stock Is Going Strong: Have Financials A Role To Play?

What Kind Of Investors Own Most Of Sequent Scientific Limited (NSE:SEQUENT)?

Dec 24
What Kind Of Investors Own Most Of Sequent Scientific Limited (NSE:SEQUENT)?

Have Sequent Scientific Limited (NSE:SEQUENT) Insiders Been Selling Their Stock?

Dec 12
Have Sequent Scientific Limited (NSE:SEQUENT) Insiders Been Selling Their Stock?

Sequent Scientific (NSE:SEQUENT) Seems To Use Debt Rather Sparingly

Nov 22
Sequent Scientific (NSE:SEQUENT) Seems To Use Debt Rather Sparingly

Estimating The Intrinsic Value Of Sequent Scientific Limited (NSE:SEQUENT)

Nov 10
Estimating The Intrinsic Value Of Sequent Scientific Limited (NSE:SEQUENT)

The Sequent Scientific (NSE:SEQUENT) Share Price Is Up 102% And Shareholders Are Boasting About It

Oct 20
The Sequent Scientific (NSE:SEQUENT) Share Price Is Up 102% And Shareholders Are Boasting About It

How Does Sequent Scientific's (NSE:SEQUENT) CEO Pay Compare With Company Performance?

Oct 05
How Does Sequent Scientific's (NSE:SEQUENT) CEO Pay Compare With Company Performance?

Is Sequent Scientific Limited's (NSE:SEQUENT) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Sep 04
Is Sequent Scientific Limited's (NSE:SEQUENT) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Do Sequent Scientific's (NSE:SEQUENT) Earnings Warrant Your Attention?

Aug 20
Do Sequent Scientific's (NSE:SEQUENT) Earnings Warrant Your Attention?

Sequent Scientific Limited's (NSE:SEQUENT) Earnings Haven't Escaped The Attention Of Investors

Jul 30
Sequent Scientific Limited's (NSE:SEQUENT) Earnings Haven't Escaped The Attention Of Investors

Does Sequent Scientific (NSE:SEQUENT) Have A Healthy Balance Sheet?

Jul 10
Does Sequent Scientific (NSE:SEQUENT) Have A Healthy Balance Sheet?

Financial Position Analysis

Short Term Liabilities: SEQUENT's short term assets (₹7.7B) exceed its short term liabilities (₹6.0B).

Long Term Liabilities: SEQUENT's short term assets (₹7.7B) exceed its long term liabilities (₹2.2B).


Debt to Equity History and Analysis

Debt Level: SEQUENT's net debt to equity ratio (58.8%) is considered high.

Reducing Debt: SEQUENT's debt to equity ratio has increased from 40% to 67.5% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable SEQUENT has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: SEQUENT is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 34.6% per year.


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.